Shots:

• The US FDA has granted approval to Italfarmaco’s Duvyzat (givinostat), histone deacetylase (HDAC) inhibitor, to treat Duchenne muscular dystrophy (DMD) patients (6yrs. or above)
• The approval was supported by the P-III (EPIDYS) study assessing the safety & efficacy of Duvyzat (BID) vs PBO in DMD ambulant male patients (n=179, 6yrs. or above)  
• The trial met the 1EP showing a meaningful difference in time to complete the four-stair climb evaluation. Favorable outcomes were also observed across 2EPs such as NSAA & fat infiltration assessment through MRI. The findings were published in The Lancet Neurology

Ref: Italfarmaco | Image: Italfarmaco

Related News:- Nerviano Medical and Italfarmaco Sign Licensing Agreement for the Development and Commercialization of Peptide-Drug Conjugate (PDC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com